Second-line infliximab therapy for ulcerative colitis (SLIT-UC): a retrospective cohort study
Infliximab remains effective as a second-line agent in ulcerative colitis, though with reduced response and higher rates of dose escalation as compared to use first-line. These findings support its continued use while highlighting the need for optimized patient selection and treatment strategies in therapy-exposed populations.
Authors
- Mawiyah Haq (ORCID: https://orcid.org/0000-0002-9366-4193)
- Dorota Borovsky (ORCID: https://orcid.org/0000-0002-6775-6641)
- Aaron Wen
- Smita Halder (ORCID: https://orcid.org/0000-0001-5850-5640)
- H. Tran (ORCID: https://orcid.org/0009-0005-3471-273X)
- Emily CL Wong
- Sama Anvari
- Abdulrahman Albassam
- Ciarán P.C. Galts
- Neeraj Narula
- John K. Marshall
- Kevin Grossman
Institutions
- Population Health Research Institute (CA)
- McMaster University (CA)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1097/meg.0000000000003132
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00